SMARCA2 and cancer: However, we observed that in multiple established BRG1 and/or BRM-deficient cancer cell lines, GTF2H1 levels were not lowered, which is probably due to an, yet unknown, adaptation mechanism to compensate for the loss of BRM/BRG1 activity (Fig. 7).